144 related articles for article (PubMed ID: 15658306)
1. [Osteoclast-activating factors (OAF)].
Sato K
Nihon Rinsho; 2004 Dec; 62 Suppl 12():228-31. PubMed ID: 15658306
[No Abstract] [Full Text] [Related]
2. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
[TBL] [Abstract][Full Text] [Related]
3. [Molecular mechanism of bone metabolism].
Kotake S; Utagawa N; Suda T; Kamatani N
Nihon Naika Gakkai Zasshi; 2000 Oct; 89(10):2046-53. PubMed ID: 11215116
[No Abstract] [Full Text] [Related]
4. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males.
Oh KW; Rhee EJ; Lee WY; Kim SW; Baek KH; Kang MI; Yun EJ; Park CY; Ihm SH; Choi MG; Yoo HJ; Park SW
Clin Endocrinol (Oxf); 2005 Jan; 62(1):92-8. PubMed ID: 15638876
[TBL] [Abstract][Full Text] [Related]
5. Evidence of a role for RANKL in the development of myeloma bone disease.
De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
[TBL] [Abstract][Full Text] [Related]
7. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
Giuliani N; Colla S; Rizzoli V
Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
[TBL] [Abstract][Full Text] [Related]
8. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?
Dovio A; Data V; Angeli A
J Endocrinol Invest; 2005; 28(10 Suppl):14-22. PubMed ID: 16550717
[TBL] [Abstract][Full Text] [Related]
9. [Recent advance in basic research for osteoporosis].
Suda T; Miyaura C
Nihon Rinsho; 2004 Feb; 62 Suppl 2():13-20. PubMed ID: 15035090
[No Abstract] [Full Text] [Related]
10. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
Masi L; Simonini G; Piscitelli E; Del Monte F; Giani T; Cimaz R; Vierucci S; Brandi ML; Falcini F
J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262
[TBL] [Abstract][Full Text] [Related]
11. RANK ligand and the regulation of skeletal remodeling.
Bell NH
J Clin Invest; 2003 Apr; 111(8):1120-2. PubMed ID: 12697730
[No Abstract] [Full Text] [Related]
12. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
13. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury.
Maïmoun L; Couret I; Mariano-Goulart D; Dupuy AM; Micallef JP; Peruchon E; Ohanna F; Cristol JP; Rossi M; Leroux JL
Calcif Tissue Int; 2005 Jun; 76(6):404-11. PubMed ID: 15812577
[TBL] [Abstract][Full Text] [Related]
14. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
Yeung RS
J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
[No Abstract] [Full Text] [Related]
15. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
[TBL] [Abstract][Full Text] [Related]
16. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Tanaka S; Nakamura K; Takahasi N; Suda T
Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
[TBL] [Abstract][Full Text] [Related]
17. Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand.
Ziegler S; Niessner A; Richter B; Wirth S; Billensteiner E; Woloszczuk W; Slany J; Geyer G
Metabolism; 2005 Jul; 54(7):935-8. PubMed ID: 15988704
[TBL] [Abstract][Full Text] [Related]
18. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
Ferrer Cañabate J; Tovar I; Martínez P
An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
[No Abstract] [Full Text] [Related]
19. [Osteoporosis].
Chaki O
Nihon Rinsho; 2006 Apr; 64 Suppl 4():370-4. PubMed ID: 16689336
[No Abstract] [Full Text] [Related]
20. High bone density due to a mutation in LDL-receptor-related protein 5.
Hofbauer LC; Maisch B; Schaefer JR
N Engl J Med; 2002 Sep; 347(12):943-4; author reply 943-4. PubMed ID: 12240686
[No Abstract] [Full Text] [Related]
[Next] [New Search]